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DOI 10.1016/j.chembiol.2007.08.004As global killers go, dengue does not
get much press. But with an annual
toll of nearly 100 million infections and
20,000 deaths, it ranks second only
to malaria among deadly mosquito-
borne diseases. A major public health
threat in most tropical countries, the
disease has been steadily spreading
and growing more virulent. Unlike its
close cousin that causes yellow fever,
the wily dengue virus has confounded
vaccine researchers for decades. But
recent scientific advances and a
coordinated global effort could soon
change that. ‘‘We now have several
rich pipelines of vaccines and several
entities promoting them,’’ says Joa-
chim Hombach, who heads the World
Health Organization’s dengue preven-
tion program. ‘‘I am confident we will
see a vaccine in a few years.’’
Most patients infected with dengue
show no symptoms, or get dengue
fever—a self-limiting, flu-like illness.
However, about 1% of the cases turn
into dengue hemorrhagic fever, a seri-
ous condition in which blood leaks
from capillaries and collects in body
cavities. Nearly 1 patient in 20 with this
condition dies. Most victims are chil-
dren. ‘‘You have a child that has a non-
specific febrile illness,and12hours later
the child is in profound shock and
can die if not treated effectively,’’ says
Duane Gubler, director of the Asia-
Pacific Institute of Tropical Medicine
and Infectious Diseases in Honolulu.
‘‘Thiscausespanicamong theparents.’’
The dengue virus’s partner in crime,
theAedesAegyptimosquito, is a highly
domesticated insect that thrives in
crowded urban settings and transmits
the disease very efficiently. Population
growth and migration to already con-
gested cities provide the deadly duo
with an ever-increasing supply of vic-
tims. Airline travel spreads the disease
further by moving infected people and
mosquitoes between population cen-
ters. As a result, the number of coun-
tries that have experienced dengue
epidemics has quadrupled since 1970.
‘‘We’ve seen unprecedented urbani-
zation during the past 20–30 years,
and that’s what is driving epidemic
dengue,’’ says Gubler.
Attempts to eradicate A. Aegypti
have largely failed, since dengue-
affected countries typically lack the re-
sources to do this. As an alternative,
researchers are racing to develop a
vaccine. But with dengue, this is easier
said than done. The virus comes in four
major strains, or serotypes, any of
which can cause the disease. Immu-
nity against one serotype does not
protect against infection by another;
on the contrary, it may increase the
risk of getting hemorrhagic fever. To
avoid this possibility of immune-en-
hanced disease, the vaccine has to
protect simultaneously and equally
against all four serotypes, according
to Alan Barrett, director of research at
the Sealy Center for Vaccine Develop-
ment at the University of Texas in Gal-
veston. ‘‘With a vaccine cocktail like
this, it’s going to be a balancing act,’’
he says.
Testing a potential vaccine is an-
other hurdle. Unlike other mosquito-
borne diseases such asmalaria, yellow
fever, or Japanese encephalitis, den-
gue causes disease only in humans—
An unprecedented collaboration among vaccine manufac-
turers, research institutes, regulatory agencies, and other
stakeholders is generating the momentum needed to make
the dengue vaccine a reality.Chemistry & Biology 14, August 2007 ªthe virus replicates in other primates,
but produces no symptoms. Currently,
thebestmethodavailable to test aden-
gue vaccine’s efficacy in a preclinical
setting is to see if it prevents viremia
in nonhuman primates challenged
with the virus. However, this does not
predict how the vaccine will act in peo-
ple. ‘‘The great challenge from the sci-
entific point of view is that we have no
animal model for the disease,’’ says
Barrett. ‘‘The only good animal model
is humans.’’
Despite these challenges, dengue
vaccine developers have made major
strides during the past few years, and
two are now within striking distance
of licensing a product.
Researchers from the Walter Reed
Army Institute of Research and Glaxo-
SmithKline have collaborated to de-
velop a ‘‘live attenuated virus’’ vaccine
that combines weakened versions of
all four dengue types. Prior to the col-
laboration, Walter Reed researchers
had developed three prototype vac-
cines for one type, using either a live
or a killed virus or a viral envelop pro-
tein. When Walter Reed and Glaxo-
SmithKline researchers compared
the three candidates in primates, they
found that the live virus vaccine
worked the best. But when vaccines
for the four serotypes were mixed
together and administered in clinical
trials, the immune response was
weak unless the dose was repeated.
‘‘What that taught us was, when you
mix four dengue viruses together,
they interfere,’’ says Bruce Innis, a
vice president and director at the
United Kingdom-based GlaxoSmith-
Kline. ‘‘As with other combination live
viral vaccines, it is going to take more
than one dose to immunize.’’ After trial
and error, the team has found that the
vaccine could be given in two doses
spaced about 6 months apart.
Close on their heels is a live
attenuated virus vaccine from Sanofi
Pasteur. This formulation is based on2007 Elsevier Ltd All rights reserved 871
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velope and premembrane proteins
into the genome of a virus used in
the company’s very successful yellow
fever vaccine. Four such chimeras
combine to make a tetravalent dengue
vaccine that is ‘‘safe and immunogenic
for all four wild-type dengue strains,’’
according to Jean Lang, a senior direc-
tor at the Lyon, France-based multina-
tional company. In contrast, vaccines
based on weakened dengue viruses
have ‘‘failed to consistently achieve
both goals in the last decades,’’ he
says.
Innis points out that GlaxoSmith-
Kline’s vaccine might prove more ef-
fective because it contains not just
two dengue proteins, but the entire
virus. ‘‘The question is, which vaccine
gives you the minimum information
required to get an adequate immune
response,’’ he says. ‘‘That will have to
be settled through experimentation.’’
Both vaccines are currently in Phase
II trials on adults and children. Two
more chimeric vaccines are in early
development: one from the National
Institutes of Health and one from the
Centers for Disease Control, licensed
to Fort Collins, Colorado-based
InViragen.
Any vaccine made with a live, repli-
cating virus poses risks. The virus
could mutate and turn pathogenic. Vi-
ral products could trigger an adverse
immune response. And in people lack-
ing a strong immune system, even a
weak virus could be a danger. This
was highlighted during clinical trials
of the first tetravalent live virus vaccine
for dengue, developed by Mahidol
University in Thailand. Some trial sub-
jects became sick; it turned out that
one of the dengue strains had been
insufficiently weakened. ‘‘You some-
times don’t discover the safety issues
until late in development,’’ says Innis.
To reduce these risks, some manu-
facturers are developing nonreplicat-
ing dengue vaccines designed to
prime the immune system without
exposing the body to an infection.
A vaccine from GenPhar, a biotech-
nology startup in Mount Pleasant,872 Chemistry & Biology 14, August 200South Carolina, uses a pair of live but
nonreplicating adenoviruses to carry
dengue antigens. Protein-coding nu-
cleotides from two serotypes are
spliced symmetrically on either side of
each adenovirus’s genome; together,
the two recombinant viruses carry anti-
gens from all four dengue pathogens.
Primate studies show that the vaccine
is 100%effective in preventing viremia,
according to JohnDong, president and
chief scientific officer of GenPhar. ‘‘We
mimic a natural dengue infection with-
out using a dengue virus,’’ says Dong.
‘‘And we get the same type of immune
response.’’
Hawaii Biotech’s vaccine contains
no viruses, but instead has truncated
recombinant envelope proteins from
each of the four dengue serotypes.
Preliminary studies show that this
‘‘subunit’’ formulation evokes a strong
immune response in primates, says
Beth-Ann Coller, vice president for re-
search and development at the Aiea,
Hawaii-based company, which has 44
full-time employees. Hawaii Biotech’s
vaccine technology is ‘‘inherently safer
than a live vaccine, particularly for im-
munocompromised individuals,’’ ac-
cording to Coller. A further advantage
for their vaccine, she says, is that
doses could be given 1 month apart,
as opposed to the 6 month interval
live vaccine might need.
Some experts say that nonreplicat-
ing dengue vaccines provide less im-
munity than those based on a live
virus—an assertion that GenPhar and
Hawaii Biotech contest, citing favor-
able animal data. Both companies
say they hope to launch Phase I trials
soon and catch up with their multina-
tional competitors.
Dengue’s unique features make it
challenging to design a clinical trial.
Since no animal model exists, ‘‘any
clinical study has to start with humans
being the first safety model,’’ says
Robin Levis of the U.S. Food and
Drug Administration. To get good
data, subjects with pre-existing immu-
nity to one or more dengue strains
should ideally be excluded from trials.
Methods to identify such persons are7 ª2007 Elsevier Ltd All rights reservednot very reliable; furthermore, most
adults in dengue-prone regions have
already been exposed to the disease.
‘‘If you are looking for a naive popula-
tion to test the immune response, you
have your work cut out for you,’’ Levis
says.
Even with an ideal set of subjects,
testing efficacy is tricky. Researchers
can’t reliably gauge a subject’s level
of protection from their immune re-
sponse to the vaccine, says Levis.
The only reliable test, therefore, is to
observe how a vaccinated subject
responds to a real dengue infection.
In the Americas, where the disease
breaks out at unpredictable intervals,
this would be hard to do—vaccinees
might need to be monitored for several
years until the next epidemic hits. In
parts of Asia, where epidemics are
more frequent, a shorter period of
monitoring might suffice, says Levis.
The final barrier to a dengue vaccine
is not scientific, but economic. Accord-
ing to some estimates, it costs more
than abillion dollars to bring a new vac-
cine to the market. Dengue strikes
mostly in poor tropical nations that
can’t afford to pay more than a dollar
or two per vaccine dose. Normally,
this would discourage manufacturers,
but a global consortium spearheaded
by the WHO and the Pediatric Dengue
Vaccine Initiative (PDVI) is working
hard to make it a more attractive com-
mercial proposition. Funded mainly by
the Gates Foundation, PDVI supports
many manufacturers in the research,
development, evaluation, and—even-
tually—distribution of dengue vac-
cines. An unprecedented collaboration
among vaccine manufacturers, re-
search institutes, regulatory agencies,
and other stakeholders is generating
the momentum needed to make the
dengue vaccine a reality, says PDVI
director Harold Margolis. ‘‘But it is
still going to take a number of years,’’
he says. ‘‘You can’t rush vaccine
science.’’
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